Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

Recently, Zacks.com users have been paying close attention to Moderna (MRNA). This makes it worthwhile to examine what the stock has in store.

The observation that mRNA vaccines can sensitize tumors to immunotherapy has researchers eager to test how mRNA’s ability to activate the immune system could be harnessed in oncology.

A stunning new study offers early evidence that COVID-19 vaccines might have a secret superpower: a precisely timed mRNA shot could help many cancer patients live longer.

A new delivery particle developed at MIT could make mRNA vaccines more effective and potentially lower the cost per vaccine ...

Fintel reports that on November 10, 2025, B of A Securities maintained coverage of Moderna (NasdaqGS:MRNA) with a ...

Scientists have developed an experimental mRNA vaccine that, when combined with existing immunotherapy drugs, could 'teach' the immune system to recog ...

The story of the pharmaceutical company Moderna almost reads like a Hollywood screenplay. In its relatively short life, it ...

A presentation by scientists on a work group for the Centers for Disease Control and Prevention’s vaccine advisory panel ...

New research found that mRNA vaccines for COVID-19 could enhance cancer treatments and help patients live longer.

The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...